Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2023 | REGN5459, a BCMA×CD3 bispecific antibody, in R/R multiple myeloma

Attaya Suvannasankha, MD, Indiana University School of Medicine, Indianapolis, IN, discusses findings from a Phase I/II trial (NCT04083534) of REGN5459, a bispecific antibody targeting BCMA and CD3, in patients with relapsed/refractory (R/R) multiple myeloma. Preclinical studies suggested the investigational drug is safer, due to reduced risk of cytokine release syndrome (CRS). Initial findings suggests REGN5459 is well tolerated in patients, and one-year progression-free survival was additionally promising. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.